Zacks Research Issues Optimistic Outlook for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Stock analysts at Zacks Research boosted their Q2 2025 EPS estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, May 27th. Zacks Research analyst R. Department now expects that the company will post earnings of ($1.58) per share for the quarter, up from their previous forecast of ($1.61). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Zacks Research also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.36) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($5.76) EPS, Q1 2026 earnings at ($1.56) EPS, Q2 2026 earnings at ($1.59) EPS, Q3 2026 earnings at ($1.33) EPS, Q4 2026 earnings at ($1.18) EPS, FY2026 earnings at ($5.66) EPS, Q1 2027 earnings at ($1.47) EPS and FY2027 earnings at ($4.68) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same quarter last year, the business posted ($1.43) EPS. The business's quarterly revenue was up 71.6% on a year-over-year basis.

CRSP has been the topic of several other research reports. Needham & Company LLC restated a "buy" rating and set a $81.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, May 20th. Barclays decreased their price target on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research note on Friday, May 9th. Wall Street Zen upgraded shares of CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. Chardan Capital dropped their price target on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Citigroup dropped their price objective on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a report on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $71.75.

CRISPR Therapeutics Stock Up 2.8%

Shares of NASDAQ:CRSP traded up $1.02 during midday trading on Friday, reaching $37.97. The company's stock had a trading volume of 939,475 shares, compared to its average volume of 2,139,396. The firm has a market capitalization of $3.28 billion, a PE ratio of -8.69 and a beta of 1.88. CRISPR Therapeutics has a twelve month low of $30.04 and a twelve month high of $67.88. The stock has a fifty day moving average of $36.54 and a 200 day moving average of $41.32.

Insider Activity

In other news, COO Julianne Bruno sold 1,198 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now directly owns 8,263 shares in the company, valued at $350,516.46. This represents a 12.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Naimish Patel sold 3,932 shares of the stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the completion of the sale, the insider now directly owns 6,068 shares of the company's stock, valued at $218,083.92. This trade represents a 39.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 17,953 shares of company stock valued at $736,087 in the last ninety days. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. SVB Wealth LLC bought a new stake in CRISPR Therapeutics in the first quarter worth about $25,000. Costello Asset Management INC acquired a new stake in CRISPR Therapeutics during the 1st quarter worth about $27,000. Wood Tarver Financial Group LLC acquired a new stake in CRISPR Therapeutics during the 4th quarter worth about $30,000. Ameriflex Group Inc. acquired a new stake in CRISPR Therapeutics during the 4th quarter worth about $36,000. Finally, Western Pacific Wealth Management LP raised its holdings in CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after buying an additional 500 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.